Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 16/20 | 0.43 |
| ▸ | SCN1A | P35498 | 13/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29204895 | 1.00 | SCN8A (0.43) | SCN8ASCN1AGPR119JAK2JAK1 | |
| SCHEMBL30845628 | 1.00 | SCN8A (0.43) | SCN8ASCN1AGPR119JAK2JAK1 | |
| SCHEMBL19627653 | 0.91 | SCN8A (0.47) | SCN8ASCN1A | |
| SCHEMBL21773229 | 0.91 | SCN8A (0.47) | SCN8ASCN1A | |
| SCHEMBL21773225 | 0.91 | SCN8A (0.47) | SCN8ASCN1A | |
| SCHEMBL21789154 | 0.88 | SCN8A (0.40) | SCN8ASCN1AGPR119 | |
| SCHEMBL30845699 | 0.88 | SCN8A (0.40) | SCN8ASCN1AGPR119 | |
| SCHEMBL29447410 | 0.87 | SCN8A (0.45) | SCN8ASCN1AGPR119NR1D1 | |
| SCHEMBL19627673 | 0.87 | SCN8A (0.45) | SCN8ASCN1AGPR119NR1D1 | |
| SCHEMBL19627705 | 0.86 | SCN8A (0.47) | SCN8ASCN1AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638898-B | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors | 泽农医药公司 | 2024-04-09 | — | — | CN | disclosed |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2020-08-25 | — | — | US | disclosed |
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071313-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885GPR119 1639/4885 |
| US-10752623-B2 | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | SCN1A, SCN2A, SCN2B | SCN8A 6/4885SCN1A 1/4885GPR119 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.